Anti-Human CD19 Reference Antibody (Loncastuximab, RUO)
- Catalog number: BS10659
- Availability: In Stock
$176.00
- Ex Tax: $176.00
Description: Loncastuximab (BS10659) is a research-grade recombinant antibody targeting CD19. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Chimeric
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.94 mMÂ Citric acid, 16.7 mMÂ Trisodium citrate dihydrate, 6.2%Â sucrose, pHÂ 6.5, 0.01%Â Tween80
Concentration: 4.55mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CD19,DifferentiationantigenCD19,T-cellsurfaceantigenLeu-12,B-lymphocyteantigenCD19,B-lymphocytesurfaceantigenB4
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: ADCT-402,RB4v1.2-SG-3249,CAS:1875032-68-0
Background: B-lymphocyte antigen CD19 is a ~61 kDa protein. Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. CD19 is the therapeutic target of tafasitamab (Monjuvi).
References:
1. Vanshylla, K. et al. (2018) Scientific reports 8, 4244. PMID: 29523808
2. Carter, RH. et al. (1992) Science (New York, N.Y.) 256, 105-7. PMID: 1373518
3. van Zelm, MC. et al. (2006) The New England journal of medicine 354, 1901-12. PMID: 16672701
4. de Rie, MA. et al. (1989) Cellular immunology 118, 368-81. PMID: 246310
5. Wang, Y. et al. (2002) Immunity 17, 501-14. PMID: 12387743
6. Sato, S. et al. (1997) Journal of immunology (Baltimore, Md. : 1950) 159, 3278-87. PMID: 9317126
7. Buhl, AM. et al. (1997) The Journal of experimental medicine 186, 1897-910. PMID: 9382888
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Chimeric
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.94 mMÂ Citric acid, 16.7 mMÂ Trisodium citrate dihydrate, 6.2%Â sucrose, pHÂ 6.5, 0.01%Â Tween80
Concentration: 4.55mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: CD19,DifferentiationantigenCD19,T-cellsurfaceantigenLeu-12,B-lymphocyteantigenCD19,B-lymphocytesurfaceantigenB4
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: ADCT-402,RB4v1.2-SG-3249,CAS:1875032-68-0
Background: B-lymphocyte antigen CD19 is a ~61 kDa protein. Functions as a coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. CD19 is the therapeutic target of tafasitamab (Monjuvi).
References:
1. Vanshylla, K. et al. (2018) Scientific reports 8, 4244. PMID: 29523808
2. Carter, RH. et al. (1992) Science (New York, N.Y.) 256, 105-7. PMID: 1373518
3. van Zelm, MC. et al. (2006) The New England journal of medicine 354, 1901-12. PMID: 16672701
4. de Rie, MA. et al. (1989) Cellular immunology 118, 368-81. PMID: 246310
5. Wang, Y. et al. (2002) Immunity 17, 501-14. PMID: 12387743
6. Sato, S. et al. (1997) Journal of immunology (Baltimore, Md. : 1950) 159, 3278-87. PMID: 9317126
7. Buhl, AM. et al. (1997) The Journal of experimental medicine 186, 1897-910. PMID: 9382888
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
BioactivitySEC-HPLC detection for Research Grade Loncastuximab.
